Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
In the biotech industry, it can be difficult to identify a company with significant upside and limited risk. Evoke Pharma (NASDAQ:EVOK) is perhaps such a biotech stock. We believe it is deeply undervalued right now. The stock has received little attention in the media since its IPO. The result is that the stock is now being offered at a discount from the IPO price, and even the IPO price itself represents a market cap that fails to capture the value of this company. Evoke has...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|